Health Care

Stocks Highlights: Sage Therapeutics, Inc. (NASDAQ:SAGE), TearLab Corporation (NASDAQ:TEAR)

0 18

Sage Therapeutics, Inc. (NASDAQ:SAGE) initiated the shares trading at $48.68 and showed positive change of +37.33% while the stock’s final trade was registered at $ 46.21. However, its previous closing price was seen at $33.65. The stock negotiated total number of 12.47 million shares as compared to 3 months average volume of 736.31 thousand shares.

The stock price demonstrated downbeat change from its 50 day moving average of 31.46 and had been up from its 200 Day Moving Average of 34.98.

Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical firmdeveloping novel medicines to treat life-altering central nervous system disorders, recently reported positive top-line results from its Phase 2 clinical trial of SAGE-547 for the treatment of severe postpartum depression (PPD). SAGE-547 achieved the primary endpoint of a important reduction in the HAM-D score compared to placebo at 60 hours (p=0.008). This represented a greater than 20 point mean reduction in the depression scores of the SAGE-547 group at the primary endpoint of 60 hours through trial completion with a greater than 12 point difference from placebo. The statistically important difference in treatment effect began at 24 hours, (p=0.006) with an effect that was maintained at similar magnitude through to the 30-day follow-up (p=0.01).

The average true range of Sage Therapeutics, Inc.’s (SAGE) is recorded at 2.79 and the relative strength index of the stock stands 79.93. The stock price is going above to its 52 week low with 75.84% and lagging behind from its 52 week high with -40.36%. Analyst recommendation for this stock stands at 1.90. A look on the firm performance, its monthly performance is 52.06% and a quarterly performance of 32.60%. The stock price is trading upbeat from its 200 days moving average with 17.39% and up from 50 days moving average with 44.80%.

 

Brokerage Recommendations:

According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. One week ago, shares have been suggested as “BUY” from “0” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 1” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “1.5” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

 

Shares of TearLab Corporation (NASDAQ:TEAR) climbed +20.97% and ended at $0.75 greater than previous closing price of $0.62. The total 2.81 million shares were bought and sold throughout the most recent trading session more than average volume of 157.15 thousand shares.

TearLab Corporation’s (TEAR) has price-to-cash ratio of 5.99 and price to sale ratio of 1.63. and gross profit margin is 51.50%. A look on the firm performance, its monthly performance is 1.21% and a quarterly performance of 10.59%. The stock price is moving up from its 20 days moving average with 12.33% and isolated positively from 50 days moving average with 3.25%.

TearLab Corporation (TEAR) (TLB.TO) (“TearLab” or the “Company”), a firmthat develops and markets point of care ophthalmic in-vitro diagnostics, recently recognized Shire plc on its recent US Food and Drug Administration (FDA) authorization of Xiidra™ (lifitegrast ophthalmic solution) 5% for the treatment of reaches intoand symptoms of Dry Eye Disease (DED).

 

“We would like to extend our sincere congratulations to Shire on securing FDA authorization for Xiidra in the treatment of reaches intoand symptoms of DED. As the first new DED prescription therapy accepted in the U.S. in the past 13 years, this is an important milestone for the ophthalmic industry and the millions of DED patients in the U.S.   We believe Shire’s authorization will improve awareness and lead to raised participation in the DED space,” stated Seph Jensen, TearLab’s Chief Executive Officer.

Brokerage Recommendations:

According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. One week ago, shares have been suggested as “BUY” from “0” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “1” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

 

 

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

Advirtisement

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.

Newsletter